技術摘要(英)
The criteria for candidate is 1. Good MERTK and AXL kinase selectivity, 2. Good oral bioavailability (F >20%), 3. Better anti-tumor efficacy than the benchmark compound, and 4. Good safety and toxicity profiles. We have identified a candidate-like optimized lead compound BPR5K230. 5K230 produced greater anti-tumor efficacy than benchmark compound ONO-7475 in murine TNBC tumor model at the same dose.We will nominate a developmental candidate and proceed preclinical development.